Loading organizations...
Mirae Asset Capital (China) operates as a private equity firm, providing diversified investment and advisory services. It specializes in partnering with high-growth enterprises driven by technological innovation. The firm applies systematic industry research and a long-term perspective, generating sustainable returns for investors while fostering relationships with its portfolio companies.
The overarching Mirae Asset Financial Group, which includes Mirae Asset Capital (China), was founded in 1997 by Chairman Hyeon Joo Park. Park’s foundational insight emphasized a relentless pursuit of innovation and a pioneer's mindset to meet evolving global client needs. This dedication shaped the group's international footprint and dynamic asset management approach.
Mirae Asset Capital (China) primarily serves institutional investors seeking exposure to high-potential private companies and supports the innovative firms within its portfolio. The firm’s vision is to achieve excellence in investment management, helping clients realize their long-term financial objectives. It aims to be a leading strategic partner, fostering innovation and driving value across diverse global industries.
MAPS Capital has 1 tracked investment across 1 company. The latest tracked deal is $270.0M Series C in Generate Biomedicines in September 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 1, 2023 | Generate Biomedicines | $270.0M Series C | — | Alchemy Ventures, Alumni Ventures, Craft Ventures, Flagship Pioneering, Gigascale Capital, IGlobe Partners, Menlo Ventures, Morgan Creek Capital Management, Multicoin Capital, OAK HC/FT, Pareto Holdings, Picus Capital, Ripio Ventures, Stellar Capital, Upload Ventures, Tony XU, ABU Dhabi Investment Authority, Amgen Ventures, ARCH Venture Partners, Fidelity Management & Research Company, March Capital, NVentures, Pictet Alternative Advisors, T. Rowe Price Associates |